

Attorney Docket No.: RTSP-0234
Inventors: Monia and Cowser
Serial No.: 10/049,743
Filing Date: June 10, 2002
Page 2

Please amend claim 16 as follows:

C' ~~16.~~ (Amended) A method of treating a human having a disease or condition associated with PI3 kinase p110 delta comprising administering to an animal having a disease or condition associated with PI3 kinase p110 delta a therapeutically or prophylactically effective amount of an antisense compound 8 to 30 nucleobases in length targeted to a nucleic acid molecule encoding human PI3 kinase p110 delta (SEQ ID NO:1) so that expression of PI3 kinase p110 delta is inhibited.


REMARKS

This preliminary amendment is being made in response to a telephone interview with Examiner Schultz on September 12, 2002. Claims 1-2 and 4-15 have been canceled. Claim 16 has been amended to incorporate the SEQ ID NO. of the target sequence and to clarify the invention. The amendment to the claim is based on teachings throughout the specification as filed and especially at pages 1-4 and pages 77-79. No new matter has been added by this amendment.

Attorney Docket No.: RTSP-0234
Inventors: Monia and Cowser
Serial No.: 10/049,743
Filing Date: June 10, 2002
Page 3

Attached hereto is a marked up version of the changes made to the specification and claims by the current amendment. The attached page is captioned "VERSION WITH MARKINGS TO SHOW CHANGES MADE."

Respectfully submitted,



Jane Massey Licata
Registration No. 32,257

Date: October 3, 2002

Licata & Tyrrell P.C.
66 Main Street
Marlton, N.J. 08053

856-810-1515

Attorney Docket No.: RTSP-0234
Inventors: Monia and Cowser
Serial No.: 10/049,743
Filing Date: June 10, 2002
Page 4

VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the claims:

Claims 1-2 and 4-15 have been canceled.

Claim 16 has been amended as follows:

16. (Amended) A method of treating a human having a disease or condition associated with PI3 kinase p110 delta comprising administering to ~~said~~ an animal having a disease or condition associated with PI3 kinase p110 delta a therapeutically or prophylactically effective amount of an antisense compound 8 to 30 nucleobases in length targeted to a nucleic acid molecule encoding human PI3 kinase p110 delta (SEQ ID NO:1) so that expression of PI3 kinase p110 delta is inhibited.